Today: 11 June 2026
Browse Category

NASDAQ:RAPT 20 January 2026 - 22 January 2026

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···

Stock Market Today

  • Telesat (TSAT) Valuation Assessed After Significant Share Price Increase
    June 10, 2026, 7:32 PM EDT. Telesat (TSAT) shares surged 405% over three years but dropped 20% last month, trading at $43.89. The company reports CA$388.3 million revenue with a CA$185.3 million loss. Telesat's Price-to-Sales (P/S) ratio stands at 2.4x, above the US Telecom average of 1.3x and peer average of 2.3x, indicating relatively high investor expectations. However, a regression-based fair P/S of 8.8x suggests the market may undervalue future growth if assumptions hold. Risks include dependence on Geostationary Earth Orbit (GEO) revenue and potential setbacks in Low Earth Orbit (LEO) projects. Investors are advised to weigh the significant potential upside against these operational challenges and market sentiment.

Latest articles

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

11 June 2026
Lloyds shares fell 0.98% as the FCA told Parliament that motor-finance compensation payments are now unlikely before 2027 due to legal challenges, prolonging uncertainty over redress costs and capital returns; investors must wait for clarity, with the next key update due July 30.
Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

11 June 2026
Nokia’s U.S. ADR plunged 3.25% to $13.40, extending losses after a 5.07% drop, as investors reacted to risks from Nvidia’s push into mobile-network tech, raising doubts about Nokia’s role in AI infrastructure and overshadowing new 5G and AI product launches; shares now sit 23% below last week’s high.
Go toTop